Kyntra Bio Inc

KYNB

Healthcare Biotechnology

Kyntra Bio Inc’s revenue for fiscal 2025 (year ended December 2025) was $6.4 million, down 78.3% from fiscal 2024.

Revenue
n/m
EPS
n/m
Free cash flow
n/m

Quarter to June 2026, against a year earlier

3.44 0.15 −4.18%
Market cap
$14.5M
P/E
0.1×
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
5/9
ROIC
0.00%
Net debt / EBITDA
2.0×
Payout ratio
—

Kyntra Bio Inc (KYNB) EV/Sales

Alert me on EV/Sales

As of 13 November 2026, Kyntra Bio Inc (KYNB) trades at a EV/Sales of 15.2×. Over the past ten years it has ranged from −1.4× (September 2023) to 35.8× (June 2018); the current reading is higher than 73% of that period. That is above the Biotechnology industry median of 8.6× and above the Healthcare sector median of 3.5×.

EV/Sales, daily

Embed this chart

Annual newest first

Period EV/Sales Change
FY2025 14.5× 392.51%
FY2024 3.0× —
FY2023 −0.3× —
FY2022 8.4× 94.12%
FY2021 4.3× (71.69%)
FY2020 15.2× 20.86%
FY2019 12.6× (20.29%)
FY2018 15.8× (32.39%)
FY2017 23.4× 262.75%
FY2016 6.4× (33.57%)

Quarterly newest first

Period EV/Sales Change
Jun 2026 18.7× 59.36%
Mar 2026 11.7× (19.27%)
Dec 2025 14.5× 53.35%
Sep 2025 9.5× (52.02%)
42 more quarters

Against its own ten years

Low −1.4× High 35.8×
Ten-year median 9.1×
Current reading's percentile 68

EV/Sales against peers

What EV/Sales is

EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.

((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)

The full definition of EV/Sales →

More on KYNB